Theravance Biopharma (NASDAQ:TBPH) Sees Strong Trading Volume – Still a Buy?

22 Sep 2026, 15:01 by Danessa Lincoln · The Markets Daily

Theravance Biopharma, Inc. (NASDAQ:TBPH – Get Free Report) shares saw unusually-high trading volume on Tuesday . Approximately 769,058 shares were traded during trading, an increase of 39% from the previous session’s volume of 554,398 shares.The stock last traded at $17.0450 and had previously closed at $17.05.

Wall Street Analysts Forecast Growth

TBPH has been the topic of a number of analyst reports. Weiss Ratings raised shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, August 17th. JonesTrading cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Monday, June 29th. Zacks Research downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, September 7th. HC Wainwright lowered shares of Theravance Biopharma from a “buy” rating to a “neutral” rating and lifted their price target for the company from $15.00 to $17.00 in a research report on Tuesday, July 7th. Finally, BTIG Research cut Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Monday, June 29th. Eight investment analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, Theravance Biopharma has a consensus rating of “Hold” and a consensus price target of $19.40.

Read Our Latest Research Report on TBPH

Theravance Biopharma Stock Performance

The business has a 50-day moving average of $16.96 and a 200-day moving average of $16.41. The stock has a market capitalization of $886.01 million, a price-to-earnings ratio of 16.90 and a beta of 0.25.

Theravance Biopharma (NASDAQ:TBPH – Get Free Report) last posted its earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.18). The company had revenue of $20.73 million during the quarter, compared to analyst estimates of $22.49 million. Theravance Biopharma had a net margin of 51.58% and a negative return on equity of 0.77%. Equities analysts predict that Theravance Biopharma, Inc. will post 1.56 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, SVP Rhonda Farnum sold 13,314 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $17.03, for a total value of $226,737.42. Following the sale, the senior vice president directly owned 213,476 shares of the company’s stock, valued at approximately $3,635,496.28. The trade was a 5.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Eli Samaha sold 37,799 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $17.00, for a total transaction of $642,583.00. Following the completion of the transaction, the insider owned 9,174,453 shares in the company, valued at approximately $155,965,701. This represents a 0.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 350,011 shares of company stock worth $6,016,830 over the last three months. Insiders own 7.65% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Pacer Advisors Inc. acquired a new stake in Theravance Biopharma during the 4th quarter worth approximately $6,342,000. Wedge Capital Management L L P NC acquired a new position in shares of Theravance Biopharma in the second quarter worth $2,190,000. Renaissance Technologies LLC acquired a new position in shares of Theravance Biopharma in the first quarter worth $2,076,000. Dimensional Fund Advisors LP increased its position in shares of Theravance Biopharma by 14.5% during the first quarter. Dimensional Fund Advisors LP now owns 983,615 shares of the biopharmaceutical company’s stock worth $15,960,000 after acquiring an additional 124,658 shares during the period. Finally, Rangeley Capital LLC purchased a new stake in shares of Theravance Biopharma during the first quarter worth $1,672,000. 99.10% of the stock is currently owned by institutional investors and hedge funds.

About Theravance Biopharma

(Get Free Report)

Theravance Biopharma, Inc is a biopharmaceutical company focused on developing and commercializing medicines for serious respiratory and immune-mediated diseases. The company’s work centers on therapies designed to address significant unmet medical needs and improve treatment options for patients.